Read by QxMD icon Read

Clinical & Translational Oncology

Q Chen, L Yao, D Burner, B Minev, L Lu, M Wang, W Ma
PURPOSE: EpCAM is a common marker used in the detection of circulating tumor cells (CTC). Disseminated cancer cells display the characteristics of epithelial-to-mesenchymal transition events. The purpose of this study was to assess the potential of epithelial membrane protein 2 (EMP2) as a novel biomarker for CTC retrieval in breast cancer. METHODS: MCF7 and MDA-MB-231 cells were stained with either anti-EpCAM or anti-EMP2 mAbs, respectively, followed by flow cytometric assay to measure their expression levels...
September 14, 2018: Clinical & Translational Oncology
N Esteve-Pérez, A Ferrer-Robles, G Gómez-Romero, D Fabián-Gonzalez, M Verd-Rodriguez, L C Mora-Fernandez, J J Segura-Sampedro, S Tejada-Gavela, R Morales-Soriano
BACKGROUND: Cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in peritoneal carcinomatosis treatment causes significant hemodynamic, metabolic, and hematological alterations. Studies on the anesthetic intraoperative management are heterogeneous and scarce. There is a great heterogeneity in the anesthetic management of CRS and HIPEC. The aim of this study is to analyze perioperative hemodynamic goal-directed management and to evaluate the complications arisen until the seventh postoperative day...
September 14, 2018: Clinical & Translational Oncology
H Guo, Z Xiang, Y Zhang, D Sun
BACKGROUND: The oxidative pentose phosphate pathway (PPP) is essential for cancer metabolism and growth. However, the contribution of 6-phosphogluconate dehydrogenase (6PGD), a key enzyme of PPP, to cervical cancer development remains largely unknown. METHODS: mRNA and protein levels of 6PGD were analyzed in cervical cancer cells and tissues derived from patients and compared to normal counterparts. Using cell culture system and xenograft mouse model, the functions of 6PGD in cervical cancer are determined and its molecular mechanism is analyzed...
September 4, 2018: Clinical & Translational Oncology
T Chen, L Tian, D Fan, F Wu, J Lu, S Ding
PURPOSE: Accumulated evidences have reminded us that since the prognosis of retroperitoneal fibrosis (RPF) secondary to non-urology carcinoma is poor it is essential to distinguish this condition from others. The objective of this study is to investigate the clinical features and outcomes of this infrequent but life-threatening disease. METHODS: A total of 97 patients diagnosed with RPF secondary to non-urology carcinoma were enrolled in this retrospective study...
September 4, 2018: Clinical & Translational Oncology
E El Rassy, T Assi, Z Bakouny, N Pavlidis, J Kattan
Metastatic urothelial carcinoma of the bladder is a rarely curable disease. Patients receive systemic therapy with limited response rates and survival benefits. The rescue regimens of these patients who have failed first-line treatment had remained problematic until the recent advances. Several trials with novel regimens, including immune checkpoint inhibitors and targeted therapy, to salvage relapsed urothelial carcinoma of the bladder have recently been published. However, the choice of an optimal treatment regimen remains challenging in the absence of randomized trials comparing regimen sequences...
September 4, 2018: Clinical & Translational Oncology
O Abdel-Rahman
BACKGROUND: The current analysis aims to provide an evaluation of the impact of diabetes mellitus (DM) on the efficacy and safety of first-line FOLFOX chemotherapy for patients with metastatic colorectal cancer (mCRC). METHODS: This is a pooled analysis of the comparator arms of two clinical trials (NCT00272051; NCT00305188) which evaluated first-line FOLFOX chemotherapy for patients with mCRC. The overall survival and progression-free survival according to patient subsets (non-diabetic and diabetic patients) were assessed through Kaplan-Meier analysis and log-rank testing...
September 4, 2018: Clinical & Translational Oncology
F Tas, K Erturk
BACKGROUND: The differences in features and risk factors for recurrence after definitive surgical excision are yet to be determined. The aim of this study was to understand these factors influencing recurrence patterns with local and regional disease in these patients. METHODS: A total of 365 relapsed patients, of whom 196 presented with local disease (stage I-II) and 169 with regional disease (stage III), were investigated in this retrospective study. RESULTS: The median time to initial recurrence for stage I-II and stage III patients was 22...
September 4, 2018: Clinical & Translational Oncology
B Farhood, N H Goradel, K Mortezaee, N Khanlarkhani, E Salehi, M S Nashtaei, H Mirtavoos-Mahyari, E Motevaseli, D Shabeeb, A E Musa, M Najafi
It is estimated that more than half of cancer patients undergo radiotherapy during the course of their treatment. Despite its beneficial therapeutic effects on tumor cells, exposure to high doses of ionizing radiation (IR) is associated with several side effects. Although improvements in radiotherapy techniques and instruments could reduce these side effects, there are still important concerns for cancer patients. For several years, scientists have been trying to modulate tumor and normal tissue responses to IR, leading to an increase in therapeutic ratio...
August 22, 2018: Clinical & Translational Oncology
X-L Hu, S-T Xu, X-C Wang, D-N Hou, C Bao, D Yang, Y-L Song
BACKGROUND: Lung cancer patients with a previous extra-pulmonary malignancy have been widely discussed for their postoperative prognosis. Still, whether different types of previous extra-pulmonary malignancy confer different clinicopathological features and outcomes of lung cancer patients deserves further investigation. METHODS: The medical records of patients undergoing operation for pulmonary malignancy were retrospectively reviewed. After identifying primary lung cancer out of pulmonary metastasis in patients with a history of previous extra-pulmonary malignancy, clinicopathological parameters and postoperative prognosis were compared between lung cancer patients without and with different types of previous extra-pulmonary malignancy...
August 21, 2018: Clinical & Translational Oncology
F Casas, I Valduvieco, G Oses, L Izquierdo, I Archila, M Costa, K S Cortes, T Barreto, F Ferrer
PURPOSE: Adjuvant radiotherapy (ART) for biochemical relapse (BR) after radical prostatectomy (RP) showed increased disease-free survival (DFS) in three previous randomized trials. Retrospective phase II trials evaluated if early salvage RT (ESRT) is equivalent to ART. Our study aims to compare ART and ESRT to salvage RT. MATERIALS AND METHODS: We compared RP plus ART and ESRT versus SRT. Indication for RT was made by PSA determination after RP: ART when PSA ≤ 0...
August 20, 2018: Clinical & Translational Oncology
C Camps Herrero, J J Reina Zoilo, D Monge Martín, F Caballero Martínez, V Guillem Porta, E Aranda Aguilar, A Carrato Mena, E Díaz-Rubio García, J García-Foncillas López, M Feijóo Saus, R López López
AIMS: To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from clinical practice with clinical oncologists' prior perception. DESIGN: Observational and descriptive study, using information collected by practising medical oncologists, at three moments: (a) questionnaire regarding their professional judgement of the handling of patients with BTcP in their practice, (b) cross-sectional clinical screening, to detect possible existing cases of BTcP in a representative sample of their patients, (c) retrospective self-audit of clinical case histories of patients diagnosed with BTcP to find out about how it has been handled...
August 9, 2018: Clinical & Translational Oncology
V Chung, F J Kos, N Hardwick, Y Yuan, J Chao, D Li, J Waisman, M Li, K Zurcher, P Frankel, D J Diamond
BACKGROUND: Vaccination of cancer patients with p53-expressing modified vaccinia Ankara virus (p53MVA) has shown in our previous studies to activate p53-reactive T cells in peripheral blood but without immediate clinical benefit. We hypothesized that the immunological responses to p53MVA vaccine may require additional immune checkpoint blockade to achieve clinically beneficial levels. We therefore conducted a phase I trial evaluating the combination of p53MVA and pembrolizumab (anti-PD-1) in patients with advanced solid tumors...
August 9, 2018: Clinical & Translational Oncology
T M Morgan, X Wang, X Qian, J M Switchenko, S Nie, K R Patel, R J Cassidy, D M Shin, J J Beitler
OBJECTIVES: We report the outcomes of patients with squamous cell carcinoma of the head and neck (HNSCC) whose circulating tumor cells (CTCs) were quantified using surface-enhanced Raman scattering (SERS) nanotechnology. METHODS: SERS tagged with EGF was used to directly measure targeted CTCs. Patient charts were retrospectively reviewed. An optimal cut point for CTCs in 7.5 ml of peripheral blood predictive of for distant metastasis-free survival (DMFS) was identified by maximizing the log-rank statistic...
August 6, 2018: Clinical & Translational Oncology
R K Singh, S Kumar, M S Tomar, P K Verma, S P Singh, P K Gautam, A Acharya
Classical protein kinase C (cPKC) enzymes are ser/thr protein kinases that have been an important factor in regulating a variety of cellular functions required for both in terms of health and disease. Therefore, precise control of cPKC-mediated signal is necessary for cellular homeostasis; however, their dysregulation leads to the development of several pathophysiological conditions including cancer. In cellular microenvironment, cPKC-mediated signaling is accompanied by multiple molecular mechanisms including phosphorylation, second messenger binding, and scaffold proteins...
July 30, 2018: Clinical & Translational Oncology
E Elez, T Quintanar, J Bosch-Barrera, J Corral, N Lainez, V Moreno, C A Rodriguez, E Gonzalez-Flores, A Cervantes
PURPOSE: The Spanish Society for Medical Oncology (SEOM, for its acronym in Spanish) and the National Commission for the Specialty of Medical Oncology seek to highlight the important workload and unrecognized dedication entailed in working as a Medical Oncology (MO) resident mentor, as well as its relevance for the quality of teaching units and the future of the specialty. MATERIALS AND METHODS: The current situation and opinion regarding the activity of MO resident mentors was analyzed by reviewing the standing national and autonomic community regulations and via an online survey targeting mentors, residents, and physicians who are not MO mentors...
July 30, 2018: Clinical & Translational Oncology
P Chen, J Zhou, J Li, Q Zhang, Q Zuo
BACKGROUND: Osteosarcoma is the most common primary malignancy of the bone, and macrophages play a promotional role during osteosarcoma development and progression. TIPE1 is known to function as a tumor suppressor in diverse cancers by inducing cell arrest and apoptosis. However, the biological function of TIPE1 in osteosarcoma is still unclear. PURPOSE: The purpose of this study was to investigate the expression and function of TIPE1 in osteosarcoma. METHODS: In the present study, TIPE1 expression in osteosarcoma cancer cells was determined by qPCR and western blotting...
July 30, 2018: Clinical & Translational Oncology
U Anido-Herranz, N Fernández-Núñez, J Afonso-Afonso, L Santomé-Couto, A Medina-Colmenero, O Fernández-Calvo, M Lázaro-Quintela, S Vázquez
Administration of chemotherapy in prostate cancer depends on patient fitness. In unfit patients, physiological impairment determines the optimum treatment. Although no consensus on assessing patient fitness currently exists, this article proposes an algorithm combining the available information for administering chemotherapy, and in particular docetaxel, in unfit patients. It was constructed by reviewing factors that can influence treatment, such as performance status, taxane-related comorbidities and nutritional status...
July 26, 2018: Clinical & Translational Oncology
S Jiang, C Hu, P Liu, M Lu
Exosomes are endosomes secreted from the membrane by exocytosis as multivesicular bodies and are generally defined by their spherical, unilamellar morphology, size and the expression of specific biomarkers used for diagnosis or therapy targets. Recent research has reported a higher relationship between exosome enrichment and tumor disease development. In this review, we discuss exosome intercellular communication and functions in the pathology of disease, especially on the cancer metastasis related with exosome...
July 26, 2018: Clinical & Translational Oncology
M Koninckx, J L Marco, I Pérez, M T Faus, V Alcolea, F Gómez
PURPOSE: New therapies with diverse mechanisms of action are available for metastatic castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC. MATERIALS AND METHODS: Observational retrospective cohort study in which mCRPC patients who initiated AA between January 1, 2012 and December 31, 2017, were included. The patients were followed-up until death or March 31, 2018...
July 18, 2018: Clinical & Translational Oncology
R Li, Q Li, S Lin, W Li, L Yu, L Wang, X Dong, L Yu, S Li, W Liu, B Li
OBJECTIVE: This study aimed to investigate the pure prognostic role of epidermal growth factor receptor (EGFR) mutation status and subtype in lung adenocarcinoma patients irrespective of therapy. MATERIALS AND METHODS: We retrospectively enrolled 119 cases of completely resected pathological stage I lung adenocarcinoma patients who received no postoperative chemotherapy or tyrosine kinase inhibitors. EGFR gene mutations from 18 to 21 exons were tested for all the patients...
July 18, 2018: Clinical & Translational Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"